NASDAQ : GALT
Galectin Therapeutics Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 3.32 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 334.82M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 6.71M | 5.79M | 5.86M | 5.94M | 6.62M | 6.36M |
| Research & Development | 8.91M | 14.29M | 36.57M | 32.13M | 31.74M | 23.82M |
| Operating Expenses | 15.62M | 20.09M | 42.43M | 38.07M | 38.35M | 30.18M |
| Operating Income | -15.62M | -20.09M | -42.43M | -38.07M | -38.35M | -30.18M |
| Interest Expense | -7.75M | -7.33M | -5.54M | -2.79M | -1.03M | -489.00K |
| Interest & Investment Income | 130.00K | 126.00K | 338.00K | 230.00K | 52.00K | 3.00K |
| Other Non Operating Income (Expenses) | -4.60M | -3.55M | 588.00K | -432.00K | 557.00K | 138.00K |
| Pretax Income | -27.84M | -30.84M | -47.05M | -41.07M | -38.78M | -30.53M |
| Net Income | -27.84M | -30.84M | -47.05M | -41.07M | -38.78M | -30.53M |
| Preferred Dividends & Other Adjustments | 184.00K | 138.00K | 153.00K | 3.74M | 97.00K | 171.00K |
| Net Income to Common | -28.03M | -30.97M | -47.20M | -44.80M | -38.87M | -30.70M |
| Shares Outstanding (Basic) | 65.15M | 63.90M | 62.31M | 60.16M | 59.39M | 58.53M |
| Shares Outstanding (Diluted) | 65.15M | 63.90M | 62.31M | 60.16M | 59.39M | 58.53M |
| EPS (Basic) | -0.43 | -0.48 | -0.76 | -0.74 | -0.65 | -0.52 |
| EPS (Diluted) | -0.43 | -0.48 | -0.76 | -0.74 | -0.65 | -0.52 |
| EBIT | -15.62M | -20.09M | -42.43M | -38.07M | -38.35M | -30.18M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 13.27M | 17.72M | 15.12M | 25.66M | 18.59M | 39.65M |
| Cash & Short-Term Investments | 13.27M | 17.72M | 15.12M | 25.66M | 18.59M | 39.65M |
| Prepaid Expenses | 1.39M | 1.71M | 2.13M | 2.04M | 1.95M | 2.17M |
| Other Current Assets | 6.00K | 6.00K | 6.00K | 6.00K | 6.00K | |
| Total Current Assets | 14.66M | 19.44M | 17.25M | 27.71M | 20.55M | 41.82M |
| Property, Plant & Equipment | 118.00K | 22.00K | 46.00K | 86.00K | ||
| Other Long-Term Assets | 49.00K | 74.00K | 243.00K | 444.00K | 647.00K | 7.00K |
| Total Assets | 14.83M | 19.53M | 17.50M | 28.20M | 21.29M | 41.83M |
| Accounts Payable | 3.73M | 3.25M | 5.66M | 6.43M | 3.89M | 1.80M |
| Accrued Expenses | 3.93M | 4.70M | 8.19M | 9.14M | 9.02M | 7.16M |
| Current Portion of Long-Term Debt | 143.84M | 21.49M | ||||
| Current Portion of Leases | 59.00K | 22.00K | 19.00K | 46.00K | 40.00K | 8.00K |
| Other Current Liabilities | 62.00K | 63.00K | 63.00K | 63.00K | 64.00K | 65.00K |
| Total Current Liabilities | 151.62M | 8.03M | 35.41M | 15.68M | 13.01M | 9.03M |
| Long-Term Debt | 137.70M | 85.16M | 72.75M | 39.83M | 29.05M | |
| Long-Term Leases | 59.00K | 20.00K | 66.00K | |||
| Other Long-Term Liabilities | 573.00K | 1.13M | ||||
| Total Liabilities | 151.68M | 145.73M | 120.56M | 88.44M | 53.48M | 39.21M |
| Common Stock | 66.00K | 65.00K | 62.00K | 61.00K | 59.00K | 59.00K |
| Additional Paid-In Capital | 307.67M | 304.07M | 296.22M | 291.85M | 275.08M | 271.00M |
| Retained Earnings | -446.79M | -432.55M | -401.57M | -354.37M | -309.57M | -270.69M |
| Total Common Equity | -139.06M | -128.41M | -105.29M | -62.46M | -34.43M | 366.00K |
| Shareholders' Equity | -136.85M | -126.19M | -103.07M | -60.24M | -32.19M | 2.62M |
| Total Liabilities & Equity | 14.83M | 19.53M | 17.50M | 28.20M | 21.29M | 41.83M |
| Total Debt | 143.96M | 137.72M | 106.66M | 72.81M | 39.93M | 29.06M |
| Net Cash (Debt) | -130.69M | -120.00M | -91.54M | -47.15M | -21.34M | 10.59M |
| Net Cash Per Share | -2.01 | -1.88 | -1.47 | -0.78 | -0.36 | 0.18 |
| Filing Date Shares Outstanding | 100.85M | 65.83M | 63.18M | 61.90M | 59.44M | 59.36M |
| Total Common Shares Outstanding | 66.31M | 65.20M | 63.16M | 61.85M | 59.43M | 59.34M |
| Working Capital | -136.96M | 11.41M | -18.16M | 12.03M | 7.54M | 32.79M |
| Book Value Per Share | -2.10 | -1.97 | -1.67 | -1.01 | -0.58 | 0.01 |
| Tangible Book Value | -139.06M | -128.41M | -105.29M | -62.46M | -34.43M | 366.00K |
| Tangible Book Value Per Share | -2.10 | -1.97 | -1.67 | -1.01 | -0.58 | 0.01 |
| Machinery | 72.00K | 72.00K | 72.00K | 72.00K | 72.00K | |
| Leasehold Improvements | 2.00K | 2.00K | 2.00K | 2.00K | 2.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -27.84M | -30.84M | -47.05M | -41.07M | -38.78M | -30.53M |
| Depreciation & Amortization | 57.00K | 53.00K | 37.00K | 33.00K | 32.00K | 41.00K |
| Stock-Based Compensation | 2.34M | 1.66M | 2.45M | 2.26M | 2.87M | 2.08M |
| Other Operating Activities | 5.31M | 4.64M | 512.00K | 1.13M | -147.00K | 145.00K |
| Change in Accounts Payable | -2.99M | -6.04M | -2.07M | 2.67M | 4.24M | 3.69M |
| Change in Other Net Operating Assets | 7.24M | 6.65M | 4.36M | 2.01M | 724.00K | 271.00K |
| Operating Cash Flow | -15.89M | -23.88M | -41.77M | -32.97M | -31.06M | -24.31M |
| Long-Term Debt Issued | 21.00M | 30.00M | 30.00M | 10.00M | 30.00M | |
| Net Debt Issued (Repaid) | 10.00M | 21.00M | 30.00M | 30.00M | 10.00M | 30.00M |
| Issuance of Common Stock | 5.39M | 5.47M | 1.23M | 10.03M | 6.81M | |
| Financing Cash Flow | 15.39M | 26.48M | 31.23M | 40.03M | 10.00M | 36.81M |
| Net Cash Flow | -502.00K | 2.60M | -10.54M | 7.07M | -21.06M | 12.51M |
| Levered Free Cash Flow | -14.86M | -20.90M | -29.31M | -20.68M | -17.56M | -13.23M |
| Unlevered Free Cash Flow | -10.01M | -16.32M | -25.84M | -18.93M | -16.91M | -12.92M |
| Change in Working Capital | 4.25M | 609.00K | 2.28M | 4.68M | 4.97M | 3.96M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 334.82M | 268.21M | 80.96M | 102.67M | 67.15M | 122.84M |
| Enterprise Value | 465.51M | 384.95M | 163.23M | 147.10M | 84.25M | 109.00M |
| Last Close Price | 3.32 | 4.16 | 1.29 | 1.66 | 1.13 | 2.07 |
| PB Ratio | -2.12 | -0.79 | -1.70 | -2.09 | 46.96 | |
| P/TBV Ratio | 335.62 | |||||
| Debt / Equity Ratio | -1.05 | -1.09 | -1.03 | -1.21 | -1.24 | 11.11 |
| Net Debt / Equity Ratio | -0.95 | -0.95 | -0.89 | -0.78 | -0.66 | -4.05 |
| Quick Ratio | 0.09 | 2.21 | 0.43 | 1.64 | 1.43 | 4.39 |
| Current Ratio | 0.10 | 2.42 | 0.49 | 1.77 | 1.58 | 4.63 |
| Return on Equity (ROE) | -227.74% | |||||
| Return on Assets (ROA) | -64.18% | -67.81% | -116.08% | -96.17% | -75.96% | -52.81% |
| Return on Capital Employed (ROCE) | 11.40% | -174.60% | 236.90% | -304.00% | -463.60% | -92.00% |
| Earnings Yield | -12.96% | -11.50% | -58.11% | -40.00% | -57.74% | -24.85% |
| Buyback Yield / Dilution | -3.55% | -2.56% | -3.57% | -1.29% | -1.48% | -2.63% |